Title: Target-Specific Oral Anticoagulation in Clinical Practice: Breaking News, Contemporary Views

Dates: April 29, 2015
Locations: Boston, MA

Learning Objectives:

- Define the various indications for the use of current and emerging target-specific oral anticoagulants
- Discuss guideline-recommended approaches to appropriate selection of venous thromboembolism treatment.
- Apply objective, evidence-based risk assessment tools to determine appropriate candidates for stroke prevention in patients with nonvalvular atrial fibrillation

Target Audience: This activity has been designed to meet the educational needs of physicians specializing in internal medicine and other primary care professionals. This activity will also be of benefit to other healthcare professionals interested in the management of thrombosis with target-specific oral anticoagulants.

Program Overview: Breaking through the “noise” on the multiple indications, uses, and trial data of current and emerging target-specific oral anticoagulants for stroke prevention in atrial fibrillation and for the primary and secondary prevention and/or acute treatment of venous thromboembolism in internal medicine, with an emphasis on imparting information about the practical and appropriate use of these agents—including the newest target-specific oral anticoagulant, which is scheduled to be approved shortly before this meeting—and recently expanded indications for an already-approved target-specific oral anticoagulant.

Major medical associations and leading experts agree that greater educational efforts are needed to inform both clinicians and patients about the appropriate use of TSOAs, which are rapidly becoming the mainstay of care in SPAF and, more recently, have provided physicians and other medical professionals with new options for the primary and secondary prevention and/or acute treatment of VTE. Patient education is acknowledged as a critical component of a successful plan of care for patients being treated with these innovative agents; therefore, Clinical and Patient Educators Association (CPEA) and Paradigm Medical Communications, LLC (Paradigm) are partnering for the Target-Specific Oral Anticoagulation in Clinical Practice: Breaking News, Contemporary Views initiative, with the important goal of engaging physicians and patients in collaborative SPAF and VTE care. This goal is based on CPEA’s well-supported premise that improving healthcare quality true understanding and
commitment from the patient, the best diagnosis and treatment approach may not yield the highest quality outcomes.”

**Faculty:**

John Fanikos, RPh, MBA  
Director of Pharmacy, Business  
Brigham and Women’s Hospital  
Boston, MA  

Christian T. Ruff, MD, MPH  
Investigator, TIMI Study Group  
Associate Physician, Cardiovascular Division  
Brigham and Women’s Hospital  
Assistant Professor of Medicine  
Harvard Medical School  
Boston, MA  

**Physician Continuing Medical Education:**  
Clinical and Patient Educators Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

**Physician Credit Designation Statement:**  
Clinical and Patient Educators Association designates this enduring activity for a maximum of 1.5 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Disclosure of Conflicts of Interest:**  
Clinical and Patient Educators Association (CPEA) requires instructors, planners, managers, and other individuals and their spouses/life partners who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by CPEA for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

**Commercial Support:** This activity is supported by independent educational grants from Boehringer Ingelheim Pharmaceuticals, Inc. and Daiichi Sankyo, Inc.